Enterprise Value to EBITDA Ratio: Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics (CKPT) develops anti-tumor antibodies, leveraging the capacities of Western contract manufacturing organizations to reduce costs. However, military conflicts and sanctions are hindering biomaterial logistics and international trials. This chart reflects an EV/EBITDA multiple of , while patent protection has been weakened by pressure from pharma behemoths and FDA requirements, limiting the business's market advantage.
Summary analytical data breakdowns for checkpointtx.com (CKPT)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Checkpoint Therapeutics|CKPT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Checkpoint Therapeutics, Inc.|CKPT - Aggregate Debt Obligations|Debts to Book Capitalization Checkpoint Therapeutics Inc|CKPT - Long-Term Debt|Company Short-Term Debts Checkpoint Therapeutics|Quick Liquidity checkpointtx.com
- business earnings and investment ratios data:
CKPT - Net Profit|Expected Profit Checkpoint Therapeutics|CKPT - Market Cap to Net Income|Future Price to Earnings Checkpoint Therapeutics|CKPT - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Checkpoint Therapeutics Inc|CKPT - Operating income before deduction of amortization|Earnings per share for the last twelve months Checkpoint Therapeutics|CKPT - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months checkpointtx.com|CKPT - Net earnings per one share growth for the current year|Expected earnings per share growth for next year Checkpoint Therapeutics
Summary company analysis:Checkpoint Therapeutics, Inc CKPT
For the biotechnology sector, EV/EBITDA serves as a key measure of business value, accounting for net debt relative to operating profit. The dynamic EV/EBITDA ratio of a company demonstrates how many years are required for asset payback at the current yield level. For Checkpoint Therapeutics (CKPT), this metric reflects market expectations for the commercialization of oncology drugs through the search for a strategic partner, determining the stability of the capital structure.
Competitor analysis
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|Enterprise Value to EBITDA Ratio delcath.com DCTH|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|Business Value to Operating Income Before Depreciation AURA|Candel - EV/EBITDA Multiple|Company Value to EBITDA Accuray, Inc.|SLS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio actuatetherapeutics.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology|EV/EBITDA Multiple TuHURA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara (TARA)|FATE: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aadi Bioscience WHWK|TScan Therapeutics Inc (TCRX) - Company Value to EBITDA|Champions Oncology Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio XBiotech Inc. XBIT|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation OSTX|Enterprise Value to EBITDA Ratio RADX|ARTV (Artiva) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio ANL (Adlai Nortye Ltd.)|VERU (Veru Inc) - Business Value to Operating Income Before Depreciation|Tempest Tx - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio XLO (Xilio Therapeutics Inc)|Enochian BioSciences - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation MURA (Mural Oncology plc)|KAPA: EV/EBITDA Multiple|Company Value to EBITDA OnKure Therapeutics (OKUR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CytoMed Therapeutics Ltd|CRIS: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple APLM|EV/EBITDA Multiple tharimmune.com (THAR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Advanced Biomed ADVB|GNPX (Genprex Inc.) - Company Value to Operating Income Before Depreciation Ratio|Calidi Bio - EV/EBITDA Multiple|Company Value to EBITDA sunshinebiopharma.com|XBIO (xeneticbio.com) - Enterprise Value to EBITDA Ratio|salariuspharma.com (SLRX) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PPBT|AONC (AON) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple BGNE|Total Company Value to Operating Income Before Depreciation Ratio Elevation Oncology Inc.|EV/EBITDA Multiple ICAD (iCAD)|IKNA - Enterprise Value to EBITDA Ratio|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Viracta Therapeutics VIRX|MOR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio NAYA Biosciences Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group
